Redx Pharma is a AIM listed clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of ~80 scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus (near to Manchester). The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience.
Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Encouraging safety and pharmacokinetic data has been reported, and a Phase 2 clinical program is confirmed to start in 2022. Redx’s third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets.
Read more about our company at https://www.redxpharma.com/about-us/
If you're interested in joining us, please visit https://www.redxpharma.com to see what job vacancies we currently have.